Patents by Inventor David MONGAN

David MONGAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11972844
    Abstract: Systems and methods are provided for over the counter statin delivery to a subject. Survey results from the subject are run against a first plurality of filters. When a filter in the first plurality of filters is fired, the subject is deemed not qualified. The survey results are also run against a second plurality of filters. When a respective filter in the second plurality is fired, the subject is provided with a corresponding warning. The method proceeds to a fulfillment process when no filter in the first plurality fires and the subject has acknowledged each warning associated with each fired filter in the second plurality. The fulfillment stores the composition order, communicates a drug facts label for the statin to the subject, and authorizes, upon subject confirmation that the label has been read, provision of the statin to the subject, the authorization including a destination associated with the subject.
    Type: Grant
    Filed: May 18, 2021
    Date of Patent: April 30, 2024
    Assignee: ASTRAZENECA UK LIMITED
    Inventors: James Blasetto, Judy Firor, David Guiga, William Mongan, Robert Prybolsky, Richard L. Skelly
  • Publication number: 20230028696
    Abstract: The invention relates to a method of determining the likelihood of an individual transitioning to a first episode of psychosis (FEP), the method comprising determining the level of selected markers in a bodily fluid sample from the individual, wherein the increase or decrease in the markers is predictive of the individual transitioning to a first episode of psychosis (FEP). The invention also relates to a method of predicting the functional outcome for an individual following a first episode of psychosis (FEP), the method comprising determining the level of selected markers in a bodily fluid sample from the individual, wherein the increase or decrease in the markers is predictive of an increased risk of functional disability outcome for the individual.
    Type: Application
    Filed: December 23, 2020
    Publication date: January 26, 2023
    Applicants: THE ROYAL COLLEGE OF SURGEONS IN IRELAND, UNIVERSITY COLLEGE DUBLIN
    Inventors: David COTTER, David MONGAN, Mary CANNON, Gerard CAGNEY